Psychiatrie [Psychiatry]
Details
Serval ID
serval:BIB_FDC9A719EAC1
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Psychiatrie [Psychiatry]
Journal
Revue Médicale suisse
ISSN
1660-9379
Publication state
Published
Issued date
2009
Volume
5
Number
186
Pages
138-142
Language
french
Abstract
In 2008 there is no major breakthrough in the field of psychopharmacology. Paliperidone, (Invega), or 9-hydroxyrisperidone, the main hydroxylated metabolite of risperidone, is now available in Switzerland. It has the same pharmacodynamic profile and a different pharmacokinetic profile, linked to an extended release preparation. Bupropion, an antidepressant with noradrenergic and dopaminergic activity, is now accepted on the Swiss market for the treatment of depression under the name of Wellbutrin. Until now, its indication was limited to tobacco withdrawal (under the name of Zyban). The article also includes new data issued from the STAR*D study (concerning the efficacy of cognitive behavioural therapy) and a few remarks about the recent debate in the media about the efficacy of antidepressants.
Keywords
Antidepressive Agents/therapeutic use, Antipsychotic Agents/therapeutic use, Humans, Isoxazoles/therapeutic use, Mental Disorders/therapy, Psychotherapy, Pyrimidines/therapeutic use
Pubmed
Create date
23/11/2009 16:45
Last modification date
20/08/2019 17:28